Earnings summaries and quarterly performance for VOLITIONRX.
Executive leadership at VOLITIONRX.
Cameron Reynolds
Detailed
President and Chief Executive Officer
CEO
AR
Andrew Retter
Chief Medical Officer
GF
Gael Forterre
Chief Commercial Officer
GM
Gaetan Michel
Chief Operating Officer
JM
Jacob Micallef
Chief Scientific Officer
JK
Jasmine Kway
Chief Executive Officer, Singapore Volition Pte. Limited
LB
Louise Batchelor
Group Chief Marketing & Communications Officer
NP
Nicholas Plummer
Group General Counsel
RR
Rodney Rootsaert
Corporate Secretary
ST
Salvatore Thomas Butera
Chief Executive Officer, Volition Veterinary Diagnostics Development LLC
TH
Terig Hughes
Chief Financial Officer and Treasurer
Board of directors at VOLITIONRX.
Research analysts who have asked questions during VOLITIONRX earnings calls.
ilya zubkov
Freedom Broker
9 questions for VNRX
Also covers: GOCO, VMD
Steven Ralston
Zacks Small-Cap Research
9 questions for VNRX
Also covers: UHAL, XIN
Bruce Jackson
The Benchmark Company LLC
3 questions for VNRX
Also covers: BFRI, BLTE, BSEM +8 more
JK
Jason Kolbert
D Boral Capital
1 question for VNRX
Also covers: BCDA, CANF, HUMA +6 more
Recent press releases and 8-K filings for VNRX.
VolitionRx Prepares Reimbursement Submission for Nu.Q® Cancer Assays in France
VNRX
Product Launch
New Projects/Investments
- VolitionRx Limited is preparing a reimbursement submission for its Nu.Q® Cancer assays to French government agencies, with active support from Hospices Civils de Lyon (HCL), to enable routine, reimbursed clinical practice for lung cancer management.
- The submission is expected before the end of this quarter (Q1 2026), and once admissible, the determination of eligibility for reimbursement coverage is mandated to take no more than five months.
- Volition anticipates the introduction of Nu.Q® Cancer into routine clinical use in France by the fourth quarter of 2026, addressing a market with approximately 50,000 new lung cancer diagnoses annually.
8 days ago
VolitionRx Secures $2.0 Million in Funding
VNRX
Debt Issuance
- VolitionRx Limited secured $2.0 million in funding from Lind Global Asset Management XII LLC.
- This funding is in exchange for a $2,400,000 senior secured convertible promissory note and a five-year common stock purchase warrant to purchase up to 7,000,350 shares at an exercise price of $0.5714 per share.
- A $70,000 commitment fee will be deducted from the funding.
- The 2026 Note will be repaid in 18 consecutive monthly installments of $133,333 beginning six months from the issuance date, and its outstanding principal is convertible into common stock at $0.5714 per share.
- The proceeds from this transaction are designated for working capital purposes.
Jan 8, 2026, 10:28 PM
VolitionRx Secures $2.0 Million in Funding and Amends Previous Agreement
VNRX
Debt Issuance
New Projects/Investments
- VolitionRx Limited has entered into an amended and restated securities purchase agreement with Lind Global Asset Management XII LLC, securing $2,000,000 in aggregate gross proceeds.
- This funding involves the issuance of a $2,400,000 senior secured convertible promissory note (the "2026 Note") and a five-year common stock purchase warrant for up to 7,000,350 shares at an exercise price of $0.5714 per share.
- A $70,000 commitment fee will be deducted from the funding.
- The 2026 Note, which does not accrue interest, will be repaid in 18 consecutive monthly installments of $133,333 starting six months from issuance, and its principal is convertible into common stock at $0.5714 per share.
- This agreement supplements a previous May 2025 agreement for a $7,500,000 note and warrant, with both the 2025 and 2026 notes secured by the company's assets.
Jan 8, 2026, 2:15 PM
VolitionRx Announces Breakthrough Clinical Data for Feline Cancer Test
VNRX
Product Launch
New Projects/Investments
- VolitionRx announced clinical study results for its Nu.Q® Vet Feline assay, demonstrating over 80% detection of feline lymphomas at 100% specificity, which is expected to lead to the world's first simple, affordable blood-based liquid biopsy test for feline cancer.
- The publication of this study in a peer-reviewed journal is anticipated to unlock a $5 million contractual milestone payment.
- The company believes the addition of a feline test could potentially double its total addressable market in the companion animal space, addressing a North American veterinary oncology market projected to reach $1.77 billion by 2025.
Jan 8, 2026, 1:45 PM
VolitionRx Details Licensing Model and Product Milestones
VNRX
New Projects/Investments
Product Launch
Guidance Update
- VolitionRx operates with an asset-light, low capex, and low opex business model, focusing on commercial partnerships and out-licensing to monetize its intellectual property through upfront payments, milestone payments, recurring revenue from component sales, and royalties.
- The company has demonstrated commercial validation, notably through a partnership with Antech, which has resulted in $10 million upfront and $13 million in milestone payments received to date for Element i+ in-house analyzer licensing.
- In 2024, VolitionRx sold over 120,000 Nu.Q® Vet Cancer Tests & Components. The company is targeting multiple licensing deals in the human space in 2026, with the first deals signed in Q3 2025.
- VolitionRx expects direct sales for routine clinical use of Nu.Q® Cancer to begin in France in 1H 2026, and the CE Marked Nu.Q® NETs test is being validated for over 20 clinical utilities, with clinical sales anticipated in 2026.
Jan 8, 2026, 12:00 PM
VolitionRx Highlights Nu.Q® Platform and Commercial Strategy
VNRX
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- VolitionRx, a medical device company, focuses on cancer and sepsis diagnostics through its Nu.Q® platform, which holds 71 granted patents with coverage up to 2044.
- The company's commercial strategy involves licensing its intellectual property, having secured $23 million in licensing and its initial $1 million in revenue from its Worldwide Animal segment.
- Key products, including Nu.Q® cancer and Nu.Q® NETs, target significant markets, with a Total Addressable Market (TAM) of $4 billion for Nu.Q cancer and over $3 billion for Nu.Q NETs.
- The CE Marked Nu.Q® NETs test is currently being validated for over 20 potential clinical applications and is projected to drive clinical sales in 2026.
- Future catalysts include cancer and NETs licensing and a $5 million catalyst milestone.
Jan 8, 2026, 12:00 PM
VolitionRx Issues 2025 Business Review
VNRX
Product Launch
New Projects/Investments
Revenue Acceleration/Inflection
- VolitionRx Limited (VNRX) issued its 2025 Business Review on December 17, 2025, detailing significant advancements in commercializing its Nu.Q® platform.
- The company received its first order for Nu.Q® Cancer assays for clinical certification in lung cancer and announced the inclusion of its Nu.Q® NETs assay in a government-backed ~$7.3 million program in France for sepsis detection.
- In 2025, VolitionRx signed two key licensing agreements: one for Antiphospholipid Syndrome with Werfen and a Co-Marketing and Services Agreement with Hologic.
- VolitionRx recorded its first revenue from sales of its CE-Marked Nu.Q® NETs automated assay in the first quarter of 2025.
- The company anticipates a $5 million contractual milestone payment in early 2026 following the publication of results from its feline lymphoma clinical study.
Dec 17, 2025, 1:45 PM
VolitionRx Announces Breakthrough in Cancer Detection Technology
VNRX
Product Launch
New Projects/Investments
- VolitionRx Limited announced the preprint availability of a new manuscript detailing Capture-Seq™, a novel method and biomarkers for cancer detection.
- This technology achieves 180-fold (18,000%) enrichment by physically separating transcription factor-bound DNA, effectively removing 99% of background DNA.
- In an initial training cohort of 70 people, the method demonstrated 100% sensitivity and 100% specificity for detecting breast, prostate, lung, or colorectal cancer, including early stages.
- Volition believes this technology represents a significant commercial opportunity with an estimated annual Total Addressable Market of approximately $23 billion and is actively seeking commercial partners.
Dec 11, 2025, 2:00 PM
VolitionRx's Nu.Q® NETs Assay Included in French Sepsis Detection Program
VNRX
Product Launch
New Projects/Investments
- VolitionRx Limited's Nu.Q® NETs H3.1 assay has been selected as the sole biomarker for "DETECSEPS", a French government-funded program for the early detection of sepsis.
- The DETECSEPS Consortium was awarded approximately €6.3 million (~$7.3 million) in financing from the French government as part of the France 2030 plan.
- The program aims to address the significant global burden of sepsis, which accounts for an estimated 166 million cases annually and 21.4 million deaths in 2021.
- Volition's Nu.Q® H3.1 biomarker is noted for its established diagnostic performance in distinguishing sepsis and its prognostic utility for patient outcomes.
Dec 4, 2025, 2:00 PM
VolitionRx Announces First Sale of Nu.Q® Cancer Assays
VNRX
Product Launch
New Projects/Investments
- VolitionRx Limited (VNRX) announced the first sale of its Nu.Q® Cancer assays to Hospices Civils de Lyon, one of Europe's leading cancer centers.
- This initial sale is for the internal certification process to prepare for the introduction of the test into routine clinical practice for cancer management.
- The Nu.Q® Cancer assays are designed to provide valuable information for Non Small Cell Lung Cancer diagnosis, including survival and progression-free survival, and to help identify patients who may benefit from curative care.
- Volition's Chief Commercial Officer highlighted this as a major milestone for the commercialization and licensing of Nu.Q® in the human cancer field.
Nov 25, 2025, 1:45 PM
Quarterly earnings call transcripts for VOLITIONRX.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more